Cliramitug

Cliramitug is a monoclonal antibody targeting human transthyretin (TTR). Cliramitug binds to TTR to inhibit its amyloid-forming process, exerting activity against amyloid protein formation. Cliramitug is promising for research of disorders related to transthyretin amyloidosis, such as certain neurological and cardiovascular disorders[1].